Success Metrics

Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(33%)

Phase Distribution

Ph phase_1
1
33%
Ph early_phase_1
2
67%

Phase Distribution

3

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Early Phase 1First-in-human
2(66.7%)
Phase 1Safety & dosage
1(33.3%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Terminated(1)

Detailed Status

Not yet recruiting2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
0.0%
Most Advanced
Early Phase 1

Trials by Phase

Early Phase 12 (66.7%)
Phase 11 (33.3%)

Trials by Status

terminated133%
not_yet_recruiting267%

Recent Activity

0 active trials
Showing 3 of 3
terminatedphase_1

HPV16 E6 TCR T Cells for Cervical Carcinoma

NCT05357027
not_yet_recruitingearly_phase_1

TIL Cells for the Treatment of the Advanced Solid Tumors Patients

NCT05649618
not_yet_recruitingearly_phase_1

TCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid Tumors

NCT05648994

Clinical Trials (3)

Showing 3 of 3 trials
NCT05357027Phase 1

HPV16 E6 TCR T Cells for Cervical Carcinoma

Terminated
NCT05649618Early Phase 1

TIL Cells for the Treatment of the Advanced Solid Tumors Patients

Not Yet Recruiting
NCT05648994Early Phase 1

TCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid Tumors

Not Yet Recruiting

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3